JGI/Jamie Grill | Tetra images | Getty images
A version of this article appeared for the first time in the Healthy Bulletin returns from CNBC, which brings the latest medical care news directly to its entrance tray. Subscribe here To receive future editions.
The tariff threats, and efforts to enter the good thanks of President Donald Trump, are feeding a new wave of United States manufacturing investments of the pharmaceutical industry.
We are here to bring you a summary of these plans, which are exactly what the Trump administration wants to see at a time when the manufacture of domestic drugs has been significantly reduced.
There are no new updates on how Trump's planned rates will be seen on the imported pharmaceutical products to the United States or when they will be announced.
But medication manufacturers are already preparing for these specific pharmaceutical levies, since they deal with evolving commercial policy, and many announce new investments in the United States to build goodwill with the president.
Manufacturing reformulation can help make the drug supply chain more robust, reducing the risk of interruptions, according to a April Data statement, a data and analysis company. Even so, it could raise production costs and medicines prices, which increases affordable concerns, Globaldata said.
Here is a list of companies that have announced new investments in the United States since Trump assumed the position:
Other companies, such as GSKHe also announced US investments last year.
Meanwhile, the Pfizer CEO, Albert Bourla, said uncertainty about pharmaceutical tariffs on Tuesday is deterring the company to invest even more in the manufacture, research and development of the United States.
“If I know there will be no tariffs … then there are tremendous investments that can happen in this country, both in R&D and in manufacturing,” Bourla said when calling, adding that the company also expects “certainty.”
Do not hesitate to send any advice, suggestion, stories ideas and data to Annika in [email protected].
The latest in Medical Care Technology: ABBott CGM data will be integrated with EPIC EHR
ABBOTT laboratories On Tuesday, he announced that the data of its free -free continuous glucose monitoring systems will be integrated directly with the electronic health registration (EHR) software of Epic Systems in the United States
A continuous glucose monitor, or a CGM, is a small sensor that crosses the skin and sends glucose readings in real time to an application. Glucose is a type of sugar that people get from food, and is the main source of energy from people. Glucose management is crucial for patients with diabetes to prevent and delay serious health problems, according to disease control and prevention centers.
The integration of Abbott with EPIC will allow doctors to see the glucose data of their patients before, during and after visits, and is intended to help them access the information in a simple and processable way. ABBOTT is working with EPIC Aura software, which connects health systems with manufacturers of medical devices and diagnostic laboratories, according to a statement.
Abbott said there is more to come.
“While integration with free data is the first offer of Abbott medical devices with Epic, it is only the beginning,” said Lisa Earnhardt, executive vice president of medical devices for Abbott, in a statement. “Our goal is to expand this model to our other medical devices and care platforms connected in the future.”
ABBOTT sells a range of CGM systems, and is the market leader in space based on the number of users, according to a 2024 market model of the William Blair firm.
Dexcom, a competition CGM company, is the second largest player behind Abbott, according to William Blair. Dexcom also offers its own direct integration solution EHR, which is available for customers who use EPIC software.
A EHR is a digital version of the medical history of a patient updated by doctors and nurses. It is a crucial software within the modern medical care system of the United States. Epic, the leader of EHR in the United States, stores medical records of more than 280 million Americans.
“Diabetes requires close collaboration between patients, primary care suppliers and specialists to administer a complex and critical care plan,” said Alan Hutchison, vice president of EPIC, in the statement. “This will help everyone focus more on patient care and less on administrative obstacles.”
Do not hesitate to send any advice, suggestion, stories ideas and data to Ashley at [email protected].
